Lytix Biopharma AS – Mandatory notification of trade by Primary Insiders and close associates

 Oslo, Norway, 26 April 2024: Reference is made to the stock exchange announcement published by Lytix Biopharma AS ("Lytix" or the "Company") earlier today, on 26 April 2024, regarding a share issue of 486,377 shares (the "Offer Shares") pursuant to a board autorisation granted by the Company's extraordinary general meeting on 25 April 2024.

As of this date, the Company has been informed that the following close associates to primary insiders have been allocated Offer Shares, as set out below:

Hifo Invest AS, a close associate to primary insider, Brynjar Forbergsskog, subscribed for 38,910 Offer Shares. Hifo Invest AS was allocated 38,910.00 Offer Shares at a price of NOK 0.10 per share.

Saturn Invest AS, a close associate to primary insider, Brynjar Forbergsskog, subscribed for 38,910 Offer Shares. Saturn Invest AS was allocated 38,910.00 Offer Shares at a price of NOK 0.10 per share.

Please see the attached forms for further details about the transactions.

Disclosure regulation:

This information is subject to the disclosure requirements pursuant to article 19 of the EU Market Abuse Regulation and section 5-12 of the Norwegian Securities Trading Act.

For more information, please contact:

Gjest Breistein, CFO

+47 952 60 512

gjest.breistein@lytixbiopharma.com

About Lytix

Based in Oslo, Norway, Lytix Biopharma is a clinical-stage biotech company with a highly novel technology based on world leading research in host-defense peptide-derived molecules. Lytix Biopharma’s lead product, LTX-315, is a first-in-class oncolytic molecule representing a new principle to boost anti-cancer immunity. Lytix Biopharma has a pipeline of molecules that can work in many different cancer indications and treatment settings, both as mono- and combination therapy.